Nostopharma

Nostopharma is a preclinical stage pharmaceutical innovator developing treatments to address unmet needs in musculo-skeletal health. According to the World Health Organization (WHO), approximately 1.71 billion people worldwide have musculoskeletal conditions. Nostopharma is developing a proprietary sustained delivery nanoformulation platform that was validated with the first therapeutic product that addresses the critical issue of trauma-induced abnormal bone growth. Other complications from trauma often include post-surgical infections, severe bleeding, acute localized inflammation, chronic pain management, and other challenges. Nostopharma envisions developing a precision medicine, "on-demand" platform to facilitate flexible combination treatments in surgical settings, aiming to achieve "complication-free" recovery for millions of trauma patients. While trauma patients are treated by orthopedic surgeons for bone repair as standard care, their accompanying soft tissue trauma goes unattended. In part, this is due to the lack of medical treatments available to trauma teams and orthopedic surgeons for use in pre-hospital settings and during surgery. Nostopharma’s treatments will be administered as rapid-response measure, pre- and post-operatively, and significantly improve the outcomes for trauma patients by facilitating the complication-free recovery. For the first time, orthopedic surgery and trauma patients will be able to take potent and proven medications without exposure to their toxicities as systemic drugs. Nostopharma has assembled a world-class team and advisory board, complemented by the best-in-class contract toxicology and manufacturing organizations to de-risk product development execution. Additionally, Nostopharma’s technology offers a versatile and advanced platform for the delivery of other therapeutics, addressing unmet needs of military and civilian trauma (e.g., infections and poor pain management). Nostopharma is following a very capital-efficient pathway (505(b)2 regulatory framework) to enter in the clinic as early as 2026 direct to Phase 2 trial. Discussions with several strategic partners like Johnson&Johnson (DePuy), UBS Pharma, Pfizer, and Stryker have confirmed the potential to partner and license NP102-nano and future pipeline products for commercialization after the successful Phase 2 clinical trial.